Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.53 is 77% below its 5-year average of -0.30, near the low end of its 5-year range (-2.86–459.88).
As of the fiscal period ended Tuesday, June 30, 2026. 31.50% below its 12-month average of -0.40.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.53.
DEBT TO EQUITY RATIO
-0.53
DEBT TO EQUITY RATIO AVG TTM
-0.40
DEBT TO EQUITY RATIO AVG 3Y
-0.63
DEBT TO EQUITY RATIO AVG 5Y
-0.30
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-31.50%
CURRENT VS 3Y AVG
+16.03%
CURRENT VS 5Y AVG
-77.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 738 covered companies
CURRENT VS SECTOR MEDIAN
-583.50%
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$111.84M
Debt to Equity Ratio
-0.53
TTM Avg
-0.40
3Y Avg
-0.63
5Y Avg
-0.30
Market Cap
$112.19M
Debt to Equity Ratio
2.28
TTM Avg
3.15
3Y Avg
2.13
5Y Avg
1.28
Market Cap
$112.53M
Debt to Equity Ratio
N/A
TTM Avg
0.12
3Y Avg
0.14
5Y Avg
0.21
Market Cap
$112.51M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$110.39M
Debt to Equity Ratio
3.72
TTM Avg
2.72
3Y Avg
1.72
5Y Avg
1.15
Market Cap
$114.57M
Debt to Equity Ratio
0.15
TTM Avg
0.11
3Y Avg
0.12
5Y Avg
0.12
Market Cap
$108.78M
Debt to Equity Ratio
0.27
TTM Avg
0.66
3Y Avg
0.63
5Y Avg
0.55
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $111.84M | -0.53 | -0.40 | -0.63 | -0.30 |
| BGM Group Ltd. (BGM)vs › | $123.07M | 0.00 | 0.00 | 0.01 | 0.08 |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.19M | 2.28 | 3.15 | 2.13 | 1.28 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.53M | N/A | 0.12 | 0.14 | 0.21 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.51M | 0.01 | 0.00 | 0.00 | 0.00 |
| MaxCyte, Inc. (MXCT)vs › | $113.53M | 0.11 | 0.10 | 0.08 | 0.09 |
| Apyx Medical Corporation (APYX)vs › | $110.39M | 3.72 | 2.72 | 1.72 | 1.15 |
| Genelux Corporation (GNLX)vs › | $114.57M | 0.15 | 0.11 | 0.12 | 0.12 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $108.78M | 0.27 | 0.66 | 0.63 | 0.55 |
| Caribou Biosciences, Inc. (CRBU)vs › | $115.05M | 0.27 | 0.16 | 0.12 | 0.10 |
Debt/Equity
-0.53
Current Ratio
3.36
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.53 |
| 2026-03-31 | -0.55 |
| 2025-12-31 | -0.38 |
| 2025-09-30 | -0.25 |
| 2025-06-30 | -0.31 |
| 2025-03-31 | -0.57 |
| 2024-12-31 | -0.82 |
| 2024-09-30 | -1.38 |
| 2024-06-30 | -2.86 |
| 2024-03-31 | -0.44 |
| 2023-12-31 | -0.58 |
| 2023-09-30 | -0.82 |
| 2023-06-30 | -0.97 |
| 2023-03-31 | -2.03 |
| 2022-12-31 | 459.88 |
| 2022-09-30 | 2.19 |
| 2022-06-30 | 1.15 |
| 2022-03-31 | 0.78 |
| 2021-12-31 | 0.60 |
| 2021-09-30 | 0.99 |
| 2021-06-30 | 0.78 |
| 2021-03-31 | 0.66 |
| 2020-12-31 | 0.56 |
| 2020-09-30 | -0.53 |
| 2020-06-30 | 3.63 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | -0.19 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
